Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 490 • 2015 ACR/ARHP Annual Meeting
Personalizing the Treat to Target Approach in Rheumatoid Arthritis
Eric M. Ruderman¹, Jennifer Beaumont², Azra Muftic², Arthur M. Mandelin II¹, Amy Eisenstein², George J. Greene² and David Cella², ¹Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The treat to target (T2T) approach has become part of the standard of care in RA management. Implicit in this approach is patient involvement…
Abstract Number: 2735 • 2015 ACR/ARHP Annual Meeting
Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li², E Alemao³, S Deveikis¹ and J Kremer⁵, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: It has been postulated that patients with longstanding RA have more treatment-resistant disease. We propose to examine whether disease duration is an independent predictor…
Abstract Number: 507 • 2015 ACR/ARHP Annual Meeting
Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
Xin Wang¹, Arthur Kavanaugh², Désirée van der Heijde³, Maxime Dougados⁴, Stefan Florentinus¹, Yihan Li¹, Iain Sainsbury¹ and Josef S. Smolen⁵, ¹AbbVie Inc., North Chicago, IL, ²University of California San Diego, La Jolla, CA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴René Descartes University and Hôpital Cochin, Paris, France, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Adalimumab (ADA) plus methotrexate (MTX) and MTX treatments for rheumatoid arthritis (RA) have been assessed in phase 2–4 clinical trials. This meta-analysis used 5…
Abstract Number: 2743 • 2015 ACR/ARHP Annual Meeting
Treatment Target Status at 6 Months and Long-Term Outcomes at 5 Years: Analysis of Methotrexate-Naïve Patients with Rheumatoid Arthritis
Paul Emery¹, Roy Fleischmann², Stephen Xu³ and Elizabeth C. Hsia^3,4, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ³Janssen Research & Development, LLC, Spring House, PA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Management guidelines recommend patients (pts) with RA should be treated with the intent of reaching a clinical target of low disease activity or remission…
Abstract Number: 560 • 2015 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li⁵, E Alemao³, S Deveikis⁴ and J Greenberg^1,6, ¹Corrona, LLC, Southborough, MA, ²Dept of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Response to therapies may vary based on anti-citrullinated protein antibodies (ACPA) status. We compared treatment response to abatacept in ACPA-positive versus -negative RA patients…
Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…
Abstract Number: 574 • 2015 ACR/ARHP Annual Meeting
Metabolomic Profiling Predicts Outcome of Rituximab Therapy in Rheumatoid Arthritis
Shannon Sweeney¹, Arthur Kavanaugh², Alessia Lodi³, Bo Wang¹, David L. Boyle⁴, Stefano Tiziani⁵ and Monica Guma⁶, ¹University of Texas at Austin, Austin, TX, ²University of California San Diego, La Jolla, CA, ³nutritional Sciences, University of Texas at Austin, Austin, TX, ⁴Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁵Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁶Pharmacology, University of California, San Diego, La Jolla, CA
Background/Purpose: We hypothesized that characterization of patients’ metabolic profiles, utilizing both high-resolution 1H-nuclear magnetic resonance (NMR) and mass spectrometry (MS), might help predict response to…
Abstract Number: 2769 • 2015 ACR/ARHP Annual Meeting
Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Wenhui Wei¹, Keith Knapp², Li Wang³, Chieh-I Chen⁴, Gary Craig², Karen Ferguson² and Sergio Schwartzman⁵, ¹Sanofi-Aventis, Bridgewater, NJ, ²Discus Analytics, Inc., Spokane, WA, ³Director, Analytic Research, STATinMED Research, Plano, TX, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Switching of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patient treatment is common in real-world clinical practice. The context for why patients switch…
Abstract Number: 972 • 2015 ACR/ARHP Annual Meeting
A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)
Ronald F. van Vollenhoven¹, Edward C. Keystone², Vibeke Strand³, Cesar Pacheco-Tena⁴, Jiri Vencovsky⁵, Frank Behrens⁶, Daniela Zipp⁷, Faiza Rharbaoui⁸, Ralf Wolter⁹, Rolf-Dietrich Tiemann¹⁰, Luise Knierim¹¹, Rainer Schmeidl¹¹, Xuefei Zhou¹², Silke Aigner^8,13, Benjamin Daelken¹⁴ and Andrea Wartenberg-Demand^8,12, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Landseinerstr 5, Biotest AG, Dreieich, Germany, ⁸Biotest AG, Dreieich, Germany, ⁹Corporate Clinical Research, L, Biotest AG, Dreieich, Germany, ¹⁰Data Management and Outsourcing, Biotest AG, Dreieich, Germany, ¹¹Cooperate Drug Safety, Biotest AG, Dreieich, Germany, ¹²Cooperate Clinical Research, Biotest AG, Dreieich, Germany, ¹³Landsteinerstrasse 5, Biotest AG, Dreieich, Germany, ¹⁴Project Managerment Office, Biotest Pharmaceuticals Corporation, Boca Raton, FL
Background/Purpose: In autoimmune diseases reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed (1). Tregalizumab (BT-061) is a humanized, anti-CD4 mAb,…
Abstract Number: 3111 • 2015 ACR/ARHP Annual Meeting
Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)
Gerd Burmester¹, IB McInnes², JM Kremer³, P Miranda⁴, J Vencovský⁵, A Godwood⁶, M Albulescu⁶, D Close⁶ and Michael Weinblatt⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Glasgow Biomedical Research Centre, Glasgow, United Kingdom, ³The Albany Medical College, Albany, NY, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic, ⁶MedImmune, Cambridge, United Kingdom, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Modulating macrophage function through GM–CSF is a novel therapeutic approach for RA. Mavrilimumab, a fully human monoclonal antibody, which targets GM–CSFR-α, has demonstrated efficacy…
Abstract Number: 1002 • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Early RA: Impact on Pain during the First Year of Treatment
Ellen Moholt¹, Anna-Birgitte Aga¹, Inge C Olsen¹, Hilde Berner Hammer², Till Uhlig³, Anne Katrine Kongtorp⁴, Heidi Lunoe⁴, Elin Mejdell Styrmoe⁴, Tore K. Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC study group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Pain is the symptom people with rheumatoid arthritis (RA) have prioritized highest for improvement [1]. Treating to target and aiming for remission in early…
Abstract Number: 3184 • 2015 ACR/ARHP Annual Meeting
Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
Sofia Ramiro¹, Robert B.M. Landewé², Désirée van der Heijde¹, Oliver FitzGerald³, Mikkel Østergaard^4,5, Joanne Homik⁶, Ori Elkayam⁷, J Carter Thorne⁸, Margaret Larche⁹, Gianfranco Ferraccioli¹⁰, Marina Backhaus¹¹, Gilles Boire¹², Bernard Combe¹³, Thierry Schaeverbeke¹⁴, Alain Saraux¹⁵, Maxime Dougados¹⁶, Silvano Adami¹⁷, Marcello Govoni¹⁸, Luigi Sinigaglia¹⁹, Alain G. Cantagrel²⁰, Cornelia F. Allaart¹, Cheryl Barnabe²¹, Clifton O. Bingham III²², Paul P. Tak²³, Dirkjan van Schaardenburg²⁴, Hilde Berner Hammer²⁵, Rana Dadashova²⁶, Edna Hutchings²⁶, Joel Paschke²⁶ and Walter Maksymowych²⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ³Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁵Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, ⁶Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁰Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹¹Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ¹³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ¹⁴Rheumatology, Pellegrin University Hospital, Bordeaux, France, ¹⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹⁶Cochin Hospital, Paris Descartes University, Paris, France, ¹⁷University of Verona, Verona, Italy, ¹⁸University of Ferrara, Ferrara, Italy, ¹⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²⁰Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ²¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²²Rheumatology, Johns Hopkins University, Baltimore, MD, ²³Division of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²⁶CaRE Arthritis, Edmonton, AB, Canada, ²⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A Treat-to-Target approach (T2T), treating patients with RA towards a target, either remission or low disease activity (T2T-REM or T2T-LDA), is nowadays recommended. However…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting
A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States
Leslie Harrold^1,2, George W. Reed^1,2, J. Timothy Harrington³, Christine J. Barr¹, Katherine C. Saunders¹, Allan Gibofsky⁴, Eric M. Ruderman⁵, Tmirah Haselkorn⁶, Jeffrey D. Greenberg^1,7, Ani John⁶ and Joel M. Kremer⁸, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Joiner Associates, LLC, Madison, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY, ⁸Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
Abstract Number: 1048 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
R Westhovens¹, Rieke Alten², Dace Pavlova³, Favio Enríquez-Sosa⁴, Minodora Mazur⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³LTD M & M Centrs, Carnikava, Latvia, ⁴CLINSTILE, S.A. DE C.V, Mexico, Mexico, ⁵IMSP Institul de Cardiologie, Chisinau, Moldova, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].